Slide 1 of 1 
Equine Receptor Antagonist (IL-1RA) Recombinant Protein
- Catalog Number:
- RP0428E
- Availability:
- In stock
- Application:
- Cell Culture, ELISA Standard, ELISpot Control, Western Blot Control
- 100% Homology:
- Equus caballus (horse)
- Equine IL-1 receptor antagonist (catalog RP0428E) is a yeast-derived cytokine supplied lyophilized without carrier protein in 10% trehalose; it has no affinity tags and is naturally endotoxin-free, and should be reconstituted in sterile PBS that contains at least 0.1% carrier protein. The protein is ~17.4 kDa, 152 amino acids long (full sequence provided), and >98% pure by SDS-PAGE, with 100% amino-acid homology to horse. Store at -20°C (stable up to twelve months from date of receipt; working aliquots with carrier protein stable ~3 months) and avoid repeated freeze/thaw cycles. Product origin is the USA. It is commonly used to study IL-1 signaling and inflammatory regulation (including inhibition of IL-1-mediated responses); typical experimental uses include cell-culture stimulation and inhibition studies, cytokine signaling assays, ELISA and neutralization assays, flow-cytometry and Western blot controls, and antibody generation/validation. Kingfisher Biotech products are supplied for research applications and are not intended for medicinal, diagnostic, or therapeutic use.
| Amino Acid Sequence | HPLGKRPCKM QAFRIWDVNQ KTFYMRNNQL VAGYLQESNT KLQEKIDVVP IEPDALFLGL HGRKLCLACV KSGDEIRFQL EAVNITDLSK NKEENKRFTF IRSNSGPTTS FESAACPGWF LCTAQEADRP VSLTNKPKES FMVTKFYLQE DQ (152) |
| Endotoxin | Naturally endotoxin-free |
| Storage Conditions | -20°C |
| Molecular Weight | 17.4 kDa |
| Purity | >98% as visualized by SDS-PAGE analysis. |
| Country Of Origin | USA |
- Equine Interleukin-1 Receptor Antagonist (IL-1Ra) is an anti-inflammatory cytokine produced by monocytes, macrophages, neutrophils, and synoviocytes in horses (Equus caballus) that functions as a key regulator of IL-1-mediated inflammation. IL-1Ra competitively binds to the IL-1 receptor type 1 (IL-1R1) without activating downstream signaling, thereby blocking the pro-inflammatory effects of IL-1α and IL-1β and limiting activation of NF-κB and MAPK pathways that drive fever, leukocyte recruitment, cartilage degradation, and systemic inflammatory responses. In equine health, IL-1Ra plays a particularly important role in musculoskeletal diseases such as osteoarthritis and synovitis, where it counteracts IL-1β-induced cartilage matrix breakdown and joint inflammation. Autologous conditioned serum (ACS) and other regenerative therapies used in performance horses often aim to increase intra-articular IL-1Ra concentrations to modulate joint inflammation. IL-1Ra is also relevant in conditions such as laminitis, colitis, endotoxemia, and systemic inflammatory response syndrome (SIRS), where balanced IL-1 signaling influences disease severity and recovery. As both a biomarker and therapeutic target, equine IL-1Ra is central to veterinary sports medicine and inflammatory disease management. In translational research, horses serve as valuable large-animal models for human osteoarthritis and inflammatory joint disease, and characterization of equine IL-1Ra supports studies of cytokine regulation, inflammasome biology, and development of targeted anti-inflammatory therapies relevant to both equine and human health.
Please choose a size to see price
RELATED MEDIA
